Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Advancing its new class of synthetic anti-infectives, Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received approval for the next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV administration – paving the way as a potential first-line treatment for patients suffering from UTI/Urosepsis.

The independent safety committee also unanimously agreed that R327 at two faster infusion rates of 2,500mg is safe and well tolerated in male and female subjects.

Moving forward, with the next cohort of subjects recruited, subject dosing will begin imminently.

Recce CEO James Graham said “We are pleased to receive the go-ahead by the Independent Safety Committee to commence dosing of R327 at two faster infusion rates of 3,000mg.

“This reaffirms the committee’s view that R327 is safe and well tolerated at two faster infusion rates of 2,500mg.

“Results from this trial will pave the way for R327 as a potential first-line treatment for patients suffering from UTI/Urosepsis.”

UTIs are responsible for about 30% of all sepsis infections, defined as ‘Urosepsis’.

R327’s potential as a treatment option across the patient's infectious disease journey positions it for therapy in this area of unmet medical need.

RECCE® 327 is an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms.

Recce Pharmaceuticals has next cohort dosing of R327 approved; paves way for UTI treatment